Loading clinical trials...

Impact of Ketoflex 12/3 Diet on Early-to-Mid Stage Alzheimer's Progression | Clinical Trials | Clareo Health

COMPLETEDNA

Impact of Ketoflex 12/3 Diet on Early-to-Mid Stage Alzheimer's Progression

Effects of Concurrent Plant-Based Ketogenic Diet and Intermittent Fasting (Ketoflex 12/3) on the Clinical Progression of Early-to-Mid Stage Alzheimer's Dementia

NCT06898424•Prof. Lutfu Hanoglu, MD

View on ClinicalTrials.gov

Summary

This study investigates the effects of the Ketoflex 12/3 diet on the clinical progression of early-to-mid stage Alzheimer's disease. The study evaluates cognitive function, metabolic changes, and overall health outcomes in participants following the Ketoflex 12/3 dietary protocol.

Eligibility

Age

50 - 85 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age between 50-85 years
•Clinical Dementia Rating (CDR) score of 0.5 or 1
•Diagnosis of Alzheimer's disease (AD) according to NINCDS-ADRDA criteria

Exclusion Criteria

•Alcohol and/or substance dependence
•Diagnosis of chronic renal failure
•Diagnosis of another neuropsychiatric disorder
•Presence of amalgam dental fillings and/or failure to have them removed following the SMART protocol

Locations (1)

Istanbul Medipol Universitesi

Istanbul, Turkey (Türkiye)

Key Dates

Start Date

March 1, 2024

Primary Completion Date

September 30, 2024

Completion Date

October 31, 2024

Last Updated

April 2, 2025

Enrollment

ACTUAL participants

Conditions

Alzheimer Type DementiaAlzheimer's Disease (AD)

Interventions

Ketoflex 12/3 Diet

BEHAVIORAL

Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease

NCT06924359

Alzheimer's Disease (AD)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 2, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions